Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
MRI is particularly valuable in pediatric care due to its non-invasive nature
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Patients can now get the starting 2.5 mg dose for $299 per month
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
Subscribe To Our Newsletter & Stay Updated
